General Gynecology · Breast Health

A Case-Control Study of Breast Cancer in Northeast of Iran: The Golestan Cohort Study

Alipour S, Omranipour R, Malekzadeh R, Poustchi H, Pourshams A, Khoshnia M, Gharavi A, Roshandel G, Eslami B

Published July 2019 Archives of Iranian Medicine, 22(7), 355-360
PMID 31679377

Abstract

Background

The incidence and survival of breast cancer (BC) vary across countries. This study aimed to determine risk factors for BC and estimate the overall survival rate in BC patients of the Golestan Cohort Study (GCS).

Methods

This case-control study was performed among participants of the GCS. Cases (N = 99) consisted of women who were diagnosed with BC and controls (n = 400) were selected out of women participating in the same cohort and had not developed any cancer during the follow-up period. Controls were frequency matched to case on both place of residency and 5-year categories of age.

Results

Considering confounding variables, logistic regression analysis manifested a reverse association between parity and BC (OR [odds ratio] = 0.87, 95% CI: 0.80-0.95, P = 0.001). In addition, we found women who had family history of any cancer (OR = 1.63, 95% CI: 1.02-2.60, P = 0.04) and long term oral contraceptive (OCP) use (≥10 years) (OR = 3.17, 95% CI: 1.27-7.95, P = 0.01) were at higher risk of BC. Of the total patients, 23 (23.2%) were died due to BC after a mean follow-up of 102.4 ± 5.31 months. Using the Kaplan-Meier analysis, the 5-year survival in these patients was 74%.

Conclusion

In the Golestan Cohort population, long term OCP use and family history of cancer were risk factors for BC, while parity was a protective factor. The 5-year survival of BC patients in the GCS is still lower relative to Europe and the United States.

Topics

By this author

Related research

General Gynecology › Breast Health › Breast Cancer Risk
Sadaf Alipour, Ramesh Omranipour, Reza Malekzadeh, Hossein Poustchi, Akram Pourshams, Masoud Khoshnia, Abdolsamad Gharavi, Gholamreza Roshandel, Bita Eslami
S Alipour, R Omranipour, R Malekzadeh, H Poustchi, A Pourshams, M Khoshnia, A Gharavi, G Roshandel, B Eslami
PMID 31679377 31679377 Alipour et al. 2019, Alipour 2019